SEC Comment Letter 0000000000-23-004672 to MoonLake Immunotherapeutics (MLTX) (CIK 0001821586) (MLTX)
MoonLake Immunotherapeutics (MLTX) (CIK 0001821586)
Date: May 4, 2023 · CIK: 0001821586 · Accession: 0000000000-23-004672
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271546
Letter
United States securities and exchange commission logo May 4, 2023 Jorge Santos da Silva, Ph.D. Chief Executive Officer MoonLake Immunotherapeutics Dorfstrasse 29 6300 Zug Switzerland Re:MoonLake Immunotherapeutics Registration Statement on Form S-3 Filed May 1, 2023 File No. 333-271546 Dear Jorge Santos da Silva: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Branden C. Berns, Esq.
Show Raw Text
United States securities and exchange commission logo
May 4, 2023
Jorge Santos da Silva, Ph.D.
Chief Executive Officer
MoonLake Immunotherapeutics
Dorfstrasse 29
6300 Zug
Switzerland
Re:MoonLake Immunotherapeutics
Registration Statement on Form S-3
Filed May 1, 2023
File No. 333-271546
Dear Jorge Santos da Silva:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Branden C. Berns, Esq.